ASCO issues guideline for febrile neutropenia in adults

Share this article:
ASCO Issues Guideline for Febrile Neutropenia in Adults
ASCO Issues Guideline for Febrile Neutropenia in Adults

(HealthDay News) -- The American Society of Clinical Oncology has issued updated recommendations for both the prevention and management of febrile episodes in neutropenic oncology outpatients; the recommendations have been published online Jan. 14 in the Journal of Clinical Oncology.

Christopher R. Flowers, M.D., from Emory University in Atlanta, and colleagues conducted a literature review and identified 43 studies assessing development of fever and/or infections in afebrile neutropenic outpatients with cancer, or treatment of fever and neutropenia in outpatients with cancer. Data extracted from the studies were used to inform guidelines.

The expert panel recommends that antibacterial and antifungal prophylaxis should only be used for patients expected to have <100 neutrophils/µL for more than seven days, unless other factors increase risks for complications or mortality to similar levels. Febrile neutropenic episodes should be managed with inpatient treatment, although carefully selected patients may be managed as outpatients, including those with a Multinational Association for Supportive Care in Cancer score of 21 or higher or those in Talcott's rules group 4. Initial doses of empirical antibacterial therapy should be received by febrile neutropenic patients within an hour of triage, and they should either be monitored for at least four hours to determine suitability for outpatient management or admitted to the hospital. Empiric therapy should include an oral fluoroquinolone plus amoxicillin/clavulanate (or plus clindamycin if penicillin allergic), unless fluoroquinolone prophylaxis was used before fever developed.

"One major limitation of the evidence available to inform this guideline is the absence of data from randomized controlled trials that either studied the net effect on health outcomes or compared the efficacy and safety of alternative regimens for antibacterial prophylaxis specifically in afebrile neutropenic outpatients," the authors write.

Full Text

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

What is this?

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.

Gene marker may help predict breast cancer response to tamoxifen

Gene marker may help predict breast cancer response ...

Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy, according to a study.

Bike riding may up prostate cancer risk

Bike riding may up prostate cancer risk

Researchers found that cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.